RIGL
insider transactionsRIGEL PHARMACEUTICALS INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-2.5K
0 buy · 2.5K sell
Net value · 90d
-$72.9K
$0 in · $72.9K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
1
0 buy · 2.5K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Dean L Schorno KEY
EVP & Chief Financial Officer
$0
2.2K sh
Own +19%
-
Exercise·M
Dean L Schorno KEY
EVP & Chief Financial Officer
$0
1.2K sh
Own +14%
-
Other·F
Dean L Schorno KEY
EVP & Chief Financial Officer
$27.7K
928 sh · $29.86
Own -1%
-
Exercise·M
Dean L Schorno KEY
EVP & Chief Financial Officer
$27.7K
2.2K sh · $12.70
Own +3%
-
Exercise·M
Dean L Schorno KEY
EVP & Chief Financial Officer
$22.4K
1.2K sh · $18.70
Own +2%
-
Other·F
EVP, Chief Commercial Officer
$26.1K
874 sh · $29.86
Own -1%
-
Other·F
EVP, Chief Medical Officer
$25.4K
850 sh · $29.86
Own -2%
-
Other·F
Raul R Rodriguez KEY
CEO, President
$72.4K
2.4K sh · $29.86
Own -1%
-
Other·F
EVP, GC, CCO & Corp Sec
$26.2K
877 sh · $29.86
Own -2%
-
Sell·S
Director · 10b5-1
$72.9K
2.5K sh · $29.17
Own -17%
-
Grant·A
Director
$0
5.8K sh
Own +46%
-
Grant·A
Director
$0
5.8K sh
Own +45%
-
Grant·A
Director
$0
5.8K sh
Own +46%
-
Grant·A
Director
$0
5.8K sh
Own +54%
-
Grant·A
Director
$0
5.8K sh
Own +460%
-
Grant·A
Director
$0
5.8K sh
Own +61%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 1, 2026 | Dean L Schorno KEY | Exercise M | 2.2K | $0 |
| Jun 1, 2026 | Dean L Schorno KEY | Exercise M | 1.2K | $0 |
| Jun 1, 2026 | Dean L Schorno KEY | Other F | 928 | $27.7K |
| Jun 1, 2026 | Dean L Schorno KEY | Exercise M | 2.2K | $27.7K |
| Jun 1, 2026 | Dean L Schorno KEY | Exercise M | 1.2K | $22.4K |
| Jun 1, 2026 | David A Santos | Other F | 874 | $26.1K |
| Jun 1, 2026 | Lisa Rojkjaer | Other F | 850 | $25.4K |
| Jun 1, 2026 | Raul R Rodriguez KEY | Other F | 2.4K | $72.4K |
| Jun 1, 2026 | Raymond J. Furey | Other F | 877 | $26.2K |
| May 26, 2026 | Kamil Ali-Jackson 10b5-1 | Sell S | 2.5K | $72.9K |
| May 15, 2026 | Jane Wasman | Grant A | 5.8K | $0 |
| May 15, 2026 | Walter H Moos | Grant A | 5.8K | $0 |
| May 15, 2026 | Anthony Gregg Lapointe | Grant A | 5.8K | $0 |
| May 15, 2026 | Alison L. Hannah | Grant A | 5.8K | $0 |
| May 15, 2026 | Mark W Frohlich | Grant A | 5.8K | $0 |
| May 15, 2026 | Kamil Ali-Jackson | Grant A | 5.8K | $0 |
About RIGL insider trading
This page tracks insider transactions for RIGEL PHARMACEUTICALS INC (RIGL) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.